Drug Landscape ›
Calcium carbonate D ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 16
Most-reported reactions
Urinary Tract Infection — 3 reports (18.75%) Asthenia — 2 reports (12.5%) Fatigue — 2 reports (12.5%) Nausea — 2 reports (12.5%) Tremor — 2 reports (12.5%) Abdominal Hernia — 1 report (6.25%) Abdominal Pain — 1 report (6.25%) Abdominal Pain Lower — 1 report (6.25%) Anaemia — 1 report (6.25%) Arthralgia — 1 report (6.25%)
Source database →
Calcium carbonate D in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Calcium carbonate D approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Calcium carbonate D in United States?
Peking University People's Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.